This Tiny Cancer Drug Upstart Just Got Even More Interesting

This Tiny Cancer Drug Upstart Just Got Even More Interesting

Loxo Oncology (NASDAQ:LOXO) was already an investors’ darling thanks to impressive efficacy for larotrectinib in a range of cancers, and after yesterday’s release of an abstract to be presented at the influential American Society of Clinical Oncology (ASCO), investors are even more optimistic about the company’s future. Will this company become the next big cancer-drug maker? A new approach to […]

Kinetic characterisation of covalent inhibitors targeting cancer drug targets

Kinetic characterisation of covalent inhibitors targeting cancer drug targets

Due to safety concerns, the pharmaceutical industry has long avoided covalent drug approaches. More recent success stories have shown that carefully tuned reactivity and specific complementarity of covalent compounds to their target can give rise to drugs with a range of advantages, particularly in the cancer field. This webinar covers biochemical strategies for characterising covalent […]

Stimuli-responsive polymeric micelles for drug delivery and cancer therapy

Stimuli-responsive polymeric micelles for drug delivery and cancer therapy

Qing Zhou,1,* Li Zhang,2,* TieHong Yang,1 Hong Wu1 1Department of Pharmaceutical Analysis, School of Pharmacy, Air Force Military Medical University, Xi’an, People’s Republic of China; 2State Key Laboratory of Military Stomatology, Air Force Military Medical University, Xi’an, People’s Republic of China *These authors contributed equally to this workAbstract: Polymeric micelles (PMs) have been widely investigated […]

Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs

Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs

GlaxoSmithKline Plc is cutting finance and accounting positions while bringing in people with cancer and science backgrounds as the U.K.’s biggest drug company shifts spending to develop its best new treatments. The new strategy has led to a “reasonable number” of job cuts, said Luke Miels, president of the London-based company’s global pharmaceutical division, declining […]

Recon: Study Halves Roche Breast Cancer Drug Treatment Time

Recon: Study Halves Roche Breast Cancer Drug Treatment Time

Posted 17 May 2018 | By Ana Mulero  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US [Paid Advertisement] Currently, approximately 70% of IVDs on the market are sold without the involvement of a Notified Body. The IVDR will change that while also making sweeping changes to medical device regulations, […]

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Every year tens of thousands of cancer researchers, doctors, investors and analysts travel to Chicago in early June for the annual meeting of the American Society of Clinical Oncology. It’s the largest conference in the drug industry’s hottest field.  Research at the conference often highlights progress from key clinical studies of cancer therapeutics, impacting the […]

Regeneron: Too 'Legit' To Quit Vs. Merck, Bristol In Lung Cancer

Regeneron: Too 'Legit' To Quit Vs. Merck, Bristol In Lung Cancer

Regeneron Pharmaceuticals‘ (REGN) experimental cancer drug “looks legit” in treating a form of lung cancer, an analyst said Thursday — meaning it could soon rival Dow Jones’ Merck (MRK) and Bristol-Myers Squibb (BMY). X All three are working on cancer drugs called PD-1 checkpoints. These immuno-oncology drugs teach the immune system to identify and fight tumor […]